Short Interest in Asterias Biotherapeutics Inc (AST) Increases By 7.8%

Asterias Biotherapeutics Inc (NYSE:AST) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 2,635,157 shares, an increase of 7.8% from the July 14th total of 2,444,930 shares. Currently, 9.8% of the company’s shares are sold short. Based on an average trading volume of 181,807 shares, the short-interest ratio is presently 14.5 days.

Several equities analysts recently issued reports on AST shares. HC Wainwright set a $12.00 price target on Asterias Biotherapeutics and gave the company a “buy” rating in a report on Monday, June 12th. Zacks Investment Research cut Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th.

Asterias Biotherapeutics (NYSE AST) opened at 3.25 on Friday. The company has a 50-day moving average price of $3.47 and a 200 day moving average price of $3.45. Asterias Biotherapeutics has a 12-month low of $2.54 and a 12-month high of $5.80. The company’s market cap is $160.10 million.

A hedge fund recently raised its stake in Asterias Biotherapeutics stock. Teachers Advisors LLC boosted its position in Asterias Biotherapeutics Inc (NYSE:AST) by 13.1% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 58,028 shares of the biotechnology company’s stock after buying an additional 6,714 shares during the period. Teachers Advisors LLC owned approximately 0.12% of Asterias Biotherapeutics worth $206,000 as of its most recent filing with the SEC.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

What are top analysts saying about Asterias Biotherapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Asterias Biotherapeutics Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit